Combining light therapy, platelet-rich plasma, and exosome therapy for children with autism
Evaluation of Combined Photo-Biomodulation At Acupuncture Points, Autologous PRP, and Umbilical Cord-Derived Exosome Therapy in Autism Spectrum Disorder: a Randomized Controlled Trial
NA · Iffat Anwar Medical Complex · NCT06600529
This study is testing a new combination of light therapy, a special blood treatment, and exosome therapy to see if it can help children with autism feel better while they continue their usual care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 3 Years to 12 Years |
| Sex | All |
| Sponsor | Iffat Anwar Medical Complex (other) |
| Locations | 1 site (Lahore, Punjab Province) |
| Trial ID | NCT06600529 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a combination of photo-biomodulation at acupuncture points, autologous platelet-rich plasma (PRP), and umbilical cord-derived exosome therapy in children diagnosed with Autism Spectrum Disorder (ASD). Participants will receive these interventions alongside standard care, with the primary goal of assessing changes in autism symptom severity using the Childhood Autism Rating Scale (CARS). The study will span six months, with multiple follow-up assessments to monitor progress and outcomes.
Who should consider this trial
Good fit: Ideal candidates are children aged 3-12 years with a diagnosis of Autism Spectrum Disorder who are stable on current medications.
Not a fit: Patients with severe comorbid medical conditions or those who have previously received stem cell or exosome therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel treatment option that significantly reduces autism symptoms in children.
How similar studies have performed: While the combination of these therapies is innovative, similar approaches in other studies have shown promise in treating various conditions, though this specific combination is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Diagnosis of Autism Spectrum Disorder based on DSM-5 criteria * Age 3-12 years * Stable on current medications for at least 4 weeks prior to study entry * Parents or legal guardians willing to provide informed consent Exclusion Criteria: * • Severe comorbid medical conditions * Prior stem cell or exosome therapy * History of hypersensitivity to any component of the interventions * Inability to comply with study procedures
Where this trial is running
Lahore, Punjab Province
- Iffat Anwar Medical Complex — Lahore, Punjab Province, Pakistan (RECRUITING)
Study contacts
- Study coordinator: Shahzad Anwar, MBBS, DOM
- Email: shahzadtirmzi@yahoo.com
- Phone: 0092 0300 9400049
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Autism Spectrum Disorder